ArticleBritish journal of haematology2022

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.

Katrina Piedra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.